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IntroductIon
The objective of RA treatment must always be guided by the 
search for minimal disease activity or remission, whose definition 
is controversial. Remission would be the only way to prevent the 
evolution to erosive and potentially deforming forms. Detecting 
the parameters that may indicate activity and prognosis of the 
disease is, therefore, of vital importance for the conduction of 
an adequate treatment.1
The main objectives of the treatment of an RA patient are: 
reducing pain, joint swelling and constitutional symptoms such 
as fatigue; improving joint function; stopping progression of 
bone-cartilage damage; preventing disabilities; and reducing 
morbidity and mortality.2
In the last years, the therapeutic concept of early RA (first 12 
months of the symptoms) has undergone great changes.3 Three 
aspects in particular came to be the basis of the new paradigm for 
treatment: early diagnosis, immediate onset of Disease Modifying 
Antirheumatic Drugs therapy (DMARD) and strict control of the 
inflammatory activity.4
 Acknowledgement of diagnosis importance and early treatment 
for RA
Once most of erosive lesions establish themselves in the first 
years of the disease, acknowledging and adequate treatment in 
this phase may prevent or slow down the disease’s progression.5
It is established that patients treated with DMARD in the first 
weeks of the disease present a better evolution than those who 
initiate the treatment later.6 
The concept of ‘window of opportunity’ emphasizes the 
need of immediate use of DMARD, associated to corticosteroids, 
aiming at the early control of the intra-articular inflammatory 
process, prevention of pannus formation and destruction of the 
damaged articulation.7
Importance of risk stratification and evolution to severe forms
There are different subgroups and subpopulations of patients with 
RA that will evolve in a diverse manner, with higher or lower severity. 
Today there is the attempt of establishing stratification models in order 
to treat the patient with a worst prognosis more agressively.7
Change in the form of prescription of therapeutic schemes
The old pyramid (sequential use of antiinflammatories, slow-
action drugs and immune-suppressive drugs) was replaced by 
the combined therapy of multiple DMARDs, since diagnosis. 
This approach prevents the patient with a more severe condition 
(presenting erosive potential) from long periods without receiving 
proper treatment.8
Use of new therapeutic agents, including biological response 
modifiers
One of the most impressive of recent advances in terms of RA 
therapy was the development of biological response modifiers (biolo-
gical agents). Although these drugs seem now the most effective medi-
cations for controlling RA, long term safety studies are still necessary. 
The use of biological agents as first therapeutic option in early RA, 
although already assessed in some studies, is rather controversial.9
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Currently the more widely used biological agents are tumor 
necrosis factor (TNF) antagonists. TNF is a potent inflamma-
tory cytokine expressed in big amounts in synovial serum and 
liquid of individuals with RA. It promotes the release of other 
inflammatory cytokines, particularly interleukins (IL) IL-1, 
IL-6, and IL-8 and stimulates the production of proteases. The 
inhibition of this cytokine has proved to be an effective and 
quick way of controlling the disease activity.10-12 Three anti-
TNF drugs are available for clinical use: infliximab (chimerical 
anti-TNF monoclonal antibody - human/murine)13, etanercept 
(fusion protein composed by the TNF soluble receptor region 
Fc of the IgC)14 and adalimumab (human antibody against 
TNF).15
Other biological therapies being used include the IL-1 
receptor antagonist (anakinra)16, anti-lymphocytes B - anti-
CD20 antibodies (rituximab)17-19, inhibitors of costimulatory 
molecules, as CTLA4-IgG fusion proteins (abatacept)20-22 and 
anticytokines, as the interleukin-6 soluble antireceptor antibody 
(tocilizumab).23-25
All the biological agents are effective in controlling articular 
manifestation and hindering the disease’s radiological progres-
sion, although there may be a therapeutic failure, especially with 
continuous treatment, in as much as 30 to 40% of the patients. A 
biological agent’s failure does not necessarily predict the absence 
of response to other drug of the same class, and the attempt of 
a new drug after the failure of the first is acceptable.9
The possible occurrence of multiple adverse effects, above all 
a higher susceptibility to various infections, including, in some 
cases, tuberculosis26, should be carefully assessed.
Another factor to be considered, especially in our milieu, is the 
high cost of these medications. More analyses of drug-economy, 
including cost-effectiveness, cost-utility, and cost-benefit of these 
therapy are needed, moreover in the early phases of the disease.27
conclusIon
There is no formal consensus on the sequence of introduction 
of medications in early RA, varying according to the severity of 
the case and the response obtained. The Update on the Brazi-
lian Consensus for the Diagnosis and Treatment of Rheumatoid 
Arthritis recommends that the choice and chronology of the 
biological agent to be prescribed be individualized, following the 
physician’s criterion.28
In short, the very early use of effective DMARDs is a key-issue 
in the treatment of patients with the risk of developing persistent 
and erosive arthritis. Intensive treatment in an early phase of 
the disease, such as the combination of DMARD with steroids 
or even biological therapies, may induce high rates of remission 
and control radiological progression.29 
This aggressive approach responds for a better prognosis than 
monotherapy with DMARD in early RA, and it must be considered 
very early for these patients. Besides that, strict monitoring of 
the disease activity, radiographical progression and prognosis 
assessment are mandatory, with the finality of adapting the 
therapeutic strategy whenever necessary.
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